首页> 外文学位 >A robust paradigm of finding the maximum tolerated dose in Phase I cancer clinical trials with application to IL-21 denenicokin
【24h】

A robust paradigm of finding the maximum tolerated dose in Phase I cancer clinical trials with application to IL-21 denenicokin

机译:在I期临床研究中将最大耐受剂量应用于IL-21 Denenicokin的最大范例

获取原文
获取原文并翻译 | 示例

摘要

In Phase I oncology trials, the main objective is typically to determine the maximum tolerated dose (MTD), the highest dose of a drug that does not cause unacceptable side effects. The MTD is determined by testing increasing doses on patient cohorts until the highest dose with acceptable side effects is found. To determine the MTD, many different dose escalation designs have been developed, such as the CRM, BLRM, mTPI-2, and BOIN, each of which has improved statistical properties over the traditional A+B class of designs. Yet most published Phase I trials still use a traditional 3+3 design. This dissertation proposes a robust paradigm of conducting Phase I cancer clinical trials that involves simultaneously running multiple designs to obtain a robust MTD. This paradigm will provide more confidence to clinicians and regulators in the selection of the dose for further drug development. The implementation of this paradigm with an application to the IL-21 denenicokin clinical development program is the focus of this dissertation.
机译:在I期肿瘤学试验中,主要目标通常是确定最大耐受剂量(MTD),即不会引起不可接受的副作用的药物的最高剂量。通过在患者队列中测试增加的剂量直至发现具有可接受的副作用的最高剂量来确定MTD。为了确定MTD,已经开发了许多不同的剂量递增设计,例如CRM,BLRM,mTPI-2和BOIN,与传统的A + B类设计相比,每种设计均具有改进的统计特性。然而,大多数已发表的I期临床试验仍使用传统的3 + 3设计。本文提出了进行I期癌症临床试验的可靠范例,该范例涉及同时运行多个设计以获得可靠的MTD。这种范例将为临床医生和管理人员在选择进一步开发药物的剂量时提供更多的信心。该范例的实现及其在IL-21 Denenicokin临床开发程序中的应用是本文的重点。

著录项

  • 作者

    Young, Tina Chang.;

  • 作者单位

    Rutgers The State University of New Jersey - New Brunswick.;

  • 授予单位 Rutgers The State University of New Jersey - New Brunswick.;
  • 学科 Biostatistics.;Oncology.;Public health.
  • 学位 D.P.H.
  • 年度 2017
  • 页码 162 p.
  • 总页数 162
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号